Racquel Bracken - Feb 22, 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role: Director
Signature: /s/ Andrew Gengos, Attorney-in-Fact
Stock symbol: CYT
Transactions as of: Feb 22, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/24/2022, 03:59 PM
Previous filing: Jun 17, 2021
Next filing: Feb 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Stock Option (Right to Buy)	Award	$0	+14.2K		$0.00	14.2K	Feb 22, 2022	Common Stock	14.2K	$5.96	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.
F2	Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported shares for the sole benefit of the Management Company and must exercise the reported shares solely upon the direction of the Management Company, which is entitled to the shares. The Management Company may be deemed the indirect beneficial owner of the reported shares, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares through her interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of her pecuniary interest therein.

Content

The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported shares for the sole benefit of the Management Company and must exercise the reported shares solely upon the direction of the Management Company, which is entitled to the shares. The Management Company may be deemed the indirect beneficial owner of the reported shares, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares through her interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of her pecuniary interest therein.